Greenovation Biotech GmbH

2019-11-20T11:27:32+01:00

L-EigenkapitalAgentur (Karlsruhe)

Other investors:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Greenovation supplies highly efficient glycoproteins for the targeted treatment of rare diseases.

Dr. Andreas Schaaf

Chief Executive

L-EigenkapitalAgentur (Karlsruhe)

Other investors:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Greenovation supplies highly efficient glycoproteins for the targeted treatment of rare diseases.

Dr. Andreas Schaaf

Chief Executive

Greenovation is a biopharmaceutical company.

As a CDMO (a contract development and manufacturing organization), Greenovation provides its customers with its own production technology for the development and production of protein-based pharmaceuticals. This “BryoTechnology” utilizes the unique advantages of the Physcomitrella patens moss and makes possible the production of a broad range of complex biopharmaceuticals.

Using its own clinical development program, Greenovation exploits the advantages of this BryoTechnology to produce highly effective glycoproteins for the treatment of orphan diseases. The lead product is alpha-galactosidase, used to treat Fabry disease.

The development of the Bryotechnology from laboratory to industrial scale became possible through the patience and the continuity of our long-standing investor and partner, the ZFHN.

Dr. Andreas Schaaf

CEO

The development of the Bryotechnology from laboratory to industrial scale became possible through the patience and the continuity of our long-standing investor and partner, the ZFHN.

Dr. Andreas Schaaf

CEO

2019
Scale-up to 500 L Bioreactors
2017
Greenovation Biotech GmbH successfully completes the clinical stage-I study of mossaGal for the treatment of Fabry disease.
2015
The German Federal Institute for Drugs and Devices gives its approval to Greenovation to begin a phase-I clinical trial in Europe for moss-aGal (agalsidase), the first-ever drug produced in moss worldwide.
2014
First-ever production of a GMP-compliant drug substance manufactured in moss for clinical use.
2012
moss-aGal enters into preclinical phase
2006
ZFHN invests in Greenovation. Following investments by LEA Eigenkapital AG and other parties in Greenovation in 2002, from this point on, ZFHN is responsible for the financing and the further development of the company.
2003
First patent granted moss-bioreactor EP1206561
1999
Founding of Greenovation Pflanzenbiotechnologie, by Prof. Dr. Gunther Neuhaus and Prof. Dr. Ralf Reski (both of the Albert Ludwigs University in Freiburg)